Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects View Full Text


Ontology type: schema:ScholarlyArticle     


Article Info

DATE

2018-12

AUTHORS

Anne Gardin, Cathy Gray, Srikanth Neelakantham, Felix Huth, Antonia M. Davidson, Swati Dumitras, Eric Legangneux, Kasra Shakeri-Nejad

ABSTRACT

PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. METHODS: This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18-45 years). In Period 1 (Days 1-12), siponimod was up-titrated from 0.25 to 2 mg over 5 days (Days 1-6) followed by 2 mg once daily on days 7-12. In Period 2, siponimod 2 mg qd was co-administered with rifampin 600 mg qd (Days 13-24). Primary assessments included PK of siponimod (Days 12 and 24; maximum steady-state plasma concentration [Cmax,ss], median time to achieve Cmax,ss [Tmax, ss], and area under the curve at steady state [AUCtau,ss]). Key secondary assessments were PK of M3 and M5 metabolites, and safety/tolerability including absolute lymphocyte count (ALC). RESULTS: Of the 16 subjects enrolled (age, mean ± standard deviation [SD] 31 ± 8.3 years; men, n = 15), 15 completed the study. In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL. In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h). Rifampin co-administration increased M3 Cmax,ss by 53% while M5 Cmax,ss remained unchanged. The AUCtau,ss of M3 and M5 decreased by 10% and 37%, respectively. The majority of adverse events reported were mild, with a higher frequency during Period 2 (86.7%) versus Period 1 (50%). The mean ALC increased slightly under rifampin co-administration but remained below 1.0 × 109/L. CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects. More... »

PAGES

1593-1604

Identifiers

URI

http://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2

DOI

http://dx.doi.org/10.1007/s00228-018-2533-2

DIMENSIONS

https://app.dimensions.ai/details/publication/pub.1106131219

PUBMED

https://www.ncbi.nlm.nih.gov/pubmed/30105453


Indexing Status Check whether this publication has been indexed by Scopus and Web Of Science using the SN Indexing Status Tool
Incoming Citations Browse incoming citations for this publication using opencitations.net

JSON-LD is the canonical representation for SciGraph data.

TIP: You can open this SciGraph record using an external JSON-LD service: JSON-LD Playground Google SDTT

[
  {
    "@context": "https://springernature.github.io/scigraph/jsonld/sgcontext.json", 
    "about": [
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/1103", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Clinical Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "id": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/11", 
        "inDefinedTermSet": "http://purl.org/au-research/vocabulary/anzsrc-for/2008/", 
        "name": "Medical and Health Sciences", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adolescent", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Adult", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Area Under Curve", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Azetidines", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Benzyl Compounds", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Biotransformation", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Cytochrome P-450 CYP2C9", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Drug Interactions", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Enzyme Induction", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Female", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Healthy Volunteers", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Humans", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Lymphocyte Count", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Male", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Receptors, Lysosphingolipid", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Rifampin", 
        "type": "DefinedTerm"
      }, 
      {
        "inDefinedTermSet": "https://www.nlm.nih.gov/mesh/", 
        "name": "Young Adult", 
        "type": "DefinedTerm"
      }
    ], 
    "author": [
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gardin", 
        "givenName": "Anne", 
        "id": "sg:person.0746041340.65", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (United States)", 
          "id": "https://www.grid.ac/institutes/grid.418424.f", 
          "name": [
            "Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Gray", 
        "givenName": "Cathy", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (India)", 
          "id": "https://www.grid.ac/institutes/grid.464975.d", 
          "name": [
            "Novartis Healthcare Pvt. Ltd., Hyderabad, India"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Neelakantham", 
        "givenName": "Srikanth", 
        "id": "sg:person.01254000765.20", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254000765.20"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Huth", 
        "givenName": "Felix", 
        "id": "sg:person.0601142577.72", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601142577.72"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Pharmaceutical Product Development (United States)", 
          "id": "https://www.grid.ac/institutes/grid.423257.5", 
          "name": [
            "PPD, Austin, TX, USA"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Davidson", 
        "givenName": "Antonia M.", 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Dumitras", 
        "givenName": "Swati", 
        "id": "sg:person.0716366542.41", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716366542.41"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Legangneux", 
        "givenName": "Eric", 
        "id": "sg:person.01152111734.09", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09"
        ], 
        "type": "Person"
      }, 
      {
        "affiliation": {
          "alternateName": "Novartis (Switzerland)", 
          "id": "https://www.grid.ac/institutes/grid.419481.1", 
          "name": [
            "Novartis Institutes for BioMedical Research, Basel, Switzerland"
          ], 
          "type": "Organization"
        }, 
        "familyName": "Shakeri-Nejad", 
        "givenName": "Kasra", 
        "id": "sg:person.01367544315.00", 
        "sameAs": [
          "https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00"
        ], 
        "type": "Person"
      }
    ], 
    "citation": [
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1365-2125.2012.04400.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1002553097"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/j.clpt.2006.08.002", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1007524447", 
          "https://doi.org/10.1016/j.clpt.2006.08.002"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1073/pnas.1014154108", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1013336301"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014227941", 
          "https://doi.org/10.2165/00003088-200342090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014227941", 
          "https://doi.org/10.2165/00003088-200342090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.2165/00003088-200342090-00003", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1014227941", 
          "https://doi.org/10.2165/00003088-200342090-00003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0002-9440(10)64794-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1017653173"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2217/pgs.10.49", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1020935714"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/rheumatology/ker018", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1022970028"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1208/s12248-012-9367-0", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1031115047", 
          "https://doi.org/10.1208/s12248-012-9367-0"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s1474-4422(13)70102-9", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033439649"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1016/j.clpt.2004.08.009", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1033907987", 
          "https://doi.org/10.1016/j.clpt.2004.08.009"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.2174/157015910792246218", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1034815003"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.109.027565", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1035576216"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1093/brain/awq118", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1041480930"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12974-016-0686-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042047657", 
          "https://doi.org/10.1186/s12974-016-0686-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12974-016-0686-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042047657", 
          "https://doi.org/10.1186/s12974-016-0686-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1186/s12974-016-0686-4", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1042047657", 
          "https://doi.org/10.1186/s12974-016-0686-4"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1476-5381.2012.02061.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1043127544"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1471-4159.2007.04629.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1045180467"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.106.010033", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1047422604"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/j.pharmthera.2007.04.006", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1050875697"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1111/j.1471-4159.2007.4629.x", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1061939563"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202369", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834516"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202588", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834626"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.5414/cp202608", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1072834636"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s00228-017-2404-2", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1099922651", 
          "https://doi.org/10.1007/s00228-017-2404-2"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1016/s0140-6736(18)30475-6", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1101698897"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "https://doi.org/10.1124/dmd.117.079574", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1103850020"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }, 
      {
        "id": "sg:pub.10.1007/s40262-018-0700-3", 
        "sameAs": [
          "https://app.dimensions.ai/details/publication/pub.1106022094", 
          "https://doi.org/10.1007/s40262-018-0700-3"
        ], 
        "type": "CreativeWork"
      }
    ], 
    "datePublished": "2018-12", 
    "datePublishedReg": "2018-12-01", 
    "description": "PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects.\nMETHODS: This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18-45\u00a0years). In Period 1 (Days 1-12), siponimod was up-titrated from 0.25 to 2\u00a0mg over 5\u00a0days (Days 1-6) followed by 2\u00a0mg once daily on days 7-12. In Period 2, siponimod 2\u00a0mg qd was co-administered with rifampin 600\u00a0mg qd (Days 13-24). Primary assessments included PK of siponimod (Days 12 and 24; maximum steady-state plasma concentration [Cmax,ss], median time to achieve Cmax,ss [Tmax, ss], and area under the curve at steady state [AUCtau,ss]). Key secondary assessments were PK of M3 and M5 metabolites, and safety/tolerability including absolute lymphocyte count (ALC).\nRESULTS: Of the 16 subjects enrolled (age, mean \u00b1 standard deviation [SD] 31\u2009\u00b1\u20098.3\u00a0years; men, n\u2009=\u200915), 15 completed the study. In Period 1, siponimod geometric mean Cmax,ss (28.6\u00a0ng/mL) was achieved in 4\u00a0h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546\u00a0h\u2009\u00d7\u2009ng/mL. In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7\u00a0ng/mL and 235\u00a0h\u2009\u00d7\u2009ng/mL, respectively; median Tmax remained unchanged (4\u00a0h). Rifampin co-administration increased M3 Cmax,ss by 53% while M5 Cmax,ss remained unchanged. The AUCtau,ss of M3 and M5 decreased by 10% and 37%, respectively. The majority of adverse events reported were mild, with a higher frequency during Period 2 (86.7%) versus Period 1 (50%). The mean ALC increased slightly under rifampin co-administration but remained below 1.0\u2009\u00d7\u2009109/L.\nCONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects.", 
    "genre": "research_article", 
    "id": "sg:pub.10.1007/s00228-018-2533-2", 
    "inLanguage": [
      "en"
    ], 
    "isAccessibleForFree": false, 
    "isPartOf": [
      {
        "id": "sg:journal.1054337", 
        "issn": [
          "0031-6970", 
          "1432-1041"
        ], 
        "name": "European Journal of Clinical Pharmacology", 
        "type": "Periodical"
      }, 
      {
        "issueNumber": "12", 
        "type": "PublicationIssue"
      }, 
      {
        "type": "PublicationVolume", 
        "volumeNumber": "74"
      }
    ], 
    "name": "Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects", 
    "pagination": "1593-1604", 
    "productId": [
      {
        "name": "readcube_id", 
        "type": "PropertyValue", 
        "value": [
          "407e2069a61a2f88a7fd2c7ae7441fb5601a5f500ea2bbbb43f66f98feb06e3b"
        ]
      }, 
      {
        "name": "pubmed_id", 
        "type": "PropertyValue", 
        "value": [
          "30105453"
        ]
      }, 
      {
        "name": "nlm_unique_id", 
        "type": "PropertyValue", 
        "value": [
          "1256165"
        ]
      }, 
      {
        "name": "doi", 
        "type": "PropertyValue", 
        "value": [
          "10.1007/s00228-018-2533-2"
        ]
      }, 
      {
        "name": "dimensions_id", 
        "type": "PropertyValue", 
        "value": [
          "pub.1106131219"
        ]
      }
    ], 
    "sameAs": [
      "https://doi.org/10.1007/s00228-018-2533-2", 
      "https://app.dimensions.ai/details/publication/pub.1106131219"
    ], 
    "sdDataset": "articles", 
    "sdDatePublished": "2019-04-11T13:19", 
    "sdLicense": "https://scigraph.springernature.com/explorer/license/", 
    "sdPublisher": {
      "name": "Springer Nature - SN SciGraph project", 
      "type": "Organization"
    }, 
    "sdSource": "s3://com-uberresearch-data-dimensions-target-20181106-alternative/cleanup/v134/2549eaecd7973599484d7c17b260dba0a4ecb94b/merge/v9/a6c9fde33151104705d4d7ff012ea9563521a3ce/jats-lookup/v90/0000000368_0000000368/records_78950_00000001.jsonl", 
    "type": "ScholarlyArticle", 
    "url": "https://link.springer.com/10.1007%2Fs00228-018-2533-2"
  }
]
 

Download the RDF metadata as:  json-ld nt turtle xml License info

HOW TO GET THIS DATA PROGRAMMATICALLY:

JSON-LD is a popular format for linked data which is fully compatible with JSON.

curl -H 'Accept: application/ld+json' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'

N-Triples is a line-based linked data format ideal for batch operations.

curl -H 'Accept: application/n-triples' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'

Turtle is a human-readable linked data format.

curl -H 'Accept: text/turtle' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'

RDF/XML is a standard XML format for linked data.

curl -H 'Accept: application/rdf+xml' 'https://scigraph.springernature.com/pub.10.1007/s00228-018-2533-2'


 

This table displays all metadata directly associated to this object as RDF triples.

278 TRIPLES      21 PREDICATES      72 URIs      38 LITERALS      26 BLANK NODES

Subject Predicate Object
1 sg:pub.10.1007/s00228-018-2533-2 schema:about N0a7ed6c5fdfe4677b735ef5f5f51898a
2 N467e9be235a84b9a9bda790d06290953
3 N4bc480b9102a4120a2f2606020fdfa63
4 N60a38bd73f844634b371a88cd2b2d0e8
5 N6d49378b3daf4d42a8aadc38992a0299
6 N9c041bf93d184dde99252cc9a53fb604
7 Na20e354d8c7a48bf869e1cce71997796
8 Nabb758d45c2b41ba9499004ecd086563
9 Nbb91ba206a174bf3b03b482b6a2d86d2
10 Nc0d28d1de42d46928e5e17f202f4933d
11 Nc3e624b965254eceb8f9fa7155dc2c80
12 Nc66aa20676a9422a983d6447b0591a5d
13 Nd5f6ee49b950401bb851217f4f0a781a
14 Ndf0b16dba7754788b65e5292f3667631
15 Ne10022fb8bff45d2b01b51189836726b
16 Neab00c28be5e4052904a5fb0fa1a9471
17 Nee9fe2109cf6424bb7dd7adc2b0bbfc8
18 anzsrc-for:11
19 anzsrc-for:1103
20 schema:author N528e24a5db054281987b74afc6332d9b
21 schema:citation sg:pub.10.1007/s00228-017-2404-2
22 sg:pub.10.1007/s40262-018-0700-3
23 sg:pub.10.1016/j.clpt.2004.08.009
24 sg:pub.10.1016/j.clpt.2006.08.002
25 sg:pub.10.1186/s12974-016-0686-4
26 sg:pub.10.1208/s12248-012-9367-0
27 sg:pub.10.2165/00003088-200342090-00003
28 https://doi.org/10.1016/j.pharmthera.2007.04.006
29 https://doi.org/10.1016/s0002-9440(10)64794-3
30 https://doi.org/10.1016/s0140-6736(18)30475-6
31 https://doi.org/10.1016/s1474-4422(13)70102-9
32 https://doi.org/10.1073/pnas.1014154108
33 https://doi.org/10.1093/brain/awq118
34 https://doi.org/10.1093/rheumatology/ker018
35 https://doi.org/10.1111/j.1365-2125.2012.04400.x
36 https://doi.org/10.1111/j.1471-4159.2007.04629.x
37 https://doi.org/10.1111/j.1471-4159.2007.4629.x
38 https://doi.org/10.1111/j.1476-5381.2012.02061.x
39 https://doi.org/10.1124/dmd.106.010033
40 https://doi.org/10.1124/dmd.109.027565
41 https://doi.org/10.1124/dmd.117.079574
42 https://doi.org/10.2174/157015910792246218
43 https://doi.org/10.2217/pgs.10.49
44 https://doi.org/10.5414/cp202369
45 https://doi.org/10.5414/cp202588
46 https://doi.org/10.5414/cp202608
47 schema:datePublished 2018-12
48 schema:datePublishedReg 2018-12-01
49 schema:description PURPOSE: To assess the potential pharmacokinetic (PK) interactions between siponimod and rifampin, a strong CYP3A4/moderate CYP2C9 inducer, in healthy subjects. METHODS: This was a confirmatory, open-label, multiple-dose two-period study in healthy subjects (aged 18-45 years). In Period 1 (Days 1-12), siponimod was up-titrated from 0.25 to 2 mg over 5 days (Days 1-6) followed by 2 mg once daily on days 7-12. In Period 2, siponimod 2 mg qd was co-administered with rifampin 600 mg qd (Days 13-24). Primary assessments included PK of siponimod (Days 12 and 24; maximum steady-state plasma concentration [Cmax,ss], median time to achieve Cmax,ss [Tmax, ss], and area under the curve at steady state [AUCtau,ss]). Key secondary assessments were PK of M3 and M5 metabolites, and safety/tolerability including absolute lymphocyte count (ALC). RESULTS: Of the 16 subjects enrolled (age, mean ± standard deviation [SD] 31 ± 8.3 years; men, n = 15), 15 completed the study. In Period 1, siponimod geometric mean Cmax,ss (28.6 ng/mL) was achieved in 4 h (median Tmax,ss; range, 1.58-8.00) and the geometric mean AUCtau,ss was 546 h × ng/mL. In Period 2, the siponimod geometric mean Cmax,ss and AUCtau,ss decreased to 15.7 ng/mL and 235 h × ng/mL, respectively; median Tmax remained unchanged (4 h). Rifampin co-administration increased M3 Cmax,ss by 53% while M5 Cmax,ss remained unchanged. The AUCtau,ss of M3 and M5 decreased by 10% and 37%, respectively. The majority of adverse events reported were mild, with a higher frequency during Period 2 (86.7%) versus Period 1 (50%). The mean ALC increased slightly under rifampin co-administration but remained below 1.0 × 109/L. CONCLUSIONS: The study findings suggest that in the presence of rifampin, a strong CYP3A4/moderate CYP2C9 inducer, siponimod showed significant decrease in Cmax,ss (45%) and AUCtau,ss (57%) in healthy subjects.
50 schema:genre research_article
51 schema:inLanguage en
52 schema:isAccessibleForFree false
53 schema:isPartOf N1569fee1e03d4b46826111d510eeef47
54 Nb29bbaffb98f43f3b8e3bfaea885af1a
55 sg:journal.1054337
56 schema:name Siponimod pharmacokinetics, safety, and tolerability in combination with rifampin, a CYP2C9/3A4 inducer, in healthy subjects
57 schema:pagination 1593-1604
58 schema:productId N1aebb2e18cf24a25a436d63a58a3c41f
59 N6323d1c753b6439fa2b5c49a16922015
60 Nce69c2a2fd4d4007bdf688d57a451356
61 Ne9aaf4f7b6694dd894b86d16e0ba3d48
62 Neda1c6593546424788470e70d330c39f
63 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106131219
64 https://doi.org/10.1007/s00228-018-2533-2
65 schema:sdDatePublished 2019-04-11T13:19
66 schema:sdLicense https://scigraph.springernature.com/explorer/license/
67 schema:sdPublisher Nedffe90db8da4470871a81368d9e347e
68 schema:url https://link.springer.com/10.1007%2Fs00228-018-2533-2
69 sgo:license sg:explorer/license/
70 sgo:sdDataset articles
71 rdf:type schema:ScholarlyArticle
72 N0a7ed6c5fdfe4677b735ef5f5f51898a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
73 schema:name Cytochrome P-450 CYP2C9
74 rdf:type schema:DefinedTerm
75 N1569fee1e03d4b46826111d510eeef47 schema:issueNumber 12
76 rdf:type schema:PublicationIssue
77 N1aebb2e18cf24a25a436d63a58a3c41f schema:name pubmed_id
78 schema:value 30105453
79 rdf:type schema:PropertyValue
80 N1e91a31c96434904ba3e2a592900ffe7 rdf:first sg:person.01367544315.00
81 rdf:rest rdf:nil
82 N467e9be235a84b9a9bda790d06290953 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
83 schema:name Humans
84 rdf:type schema:DefinedTerm
85 N48d8b92bb2f249b38349dce771c75fe7 schema:affiliation https://www.grid.ac/institutes/grid.418424.f
86 schema:familyName Gray
87 schema:givenName Cathy
88 rdf:type schema:Person
89 N4bc480b9102a4120a2f2606020fdfa63 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
90 schema:name Female
91 rdf:type schema:DefinedTerm
92 N528e24a5db054281987b74afc6332d9b rdf:first sg:person.0746041340.65
93 rdf:rest Na150e925ed4c4f739dbd181d318fc973
94 N5c32c08aa019453991eb46b77929f5eb schema:affiliation https://www.grid.ac/institutes/grid.423257.5
95 schema:familyName Davidson
96 schema:givenName Antonia M.
97 rdf:type schema:Person
98 N60a38bd73f844634b371a88cd2b2d0e8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
99 schema:name Azetidines
100 rdf:type schema:DefinedTerm
101 N6323d1c753b6439fa2b5c49a16922015 schema:name nlm_unique_id
102 schema:value 1256165
103 rdf:type schema:PropertyValue
104 N642f9aaa74724d6c8f87980ab7cc87a4 rdf:first N5c32c08aa019453991eb46b77929f5eb
105 rdf:rest N6a7c94b766d847549a25bf1b9b6c5f1c
106 N6a7c94b766d847549a25bf1b9b6c5f1c rdf:first sg:person.0716366542.41
107 rdf:rest N8c79ba433c014d89a64a732574d11c14
108 N6d49378b3daf4d42a8aadc38992a0299 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
109 schema:name Young Adult
110 rdf:type schema:DefinedTerm
111 N8c79ba433c014d89a64a732574d11c14 rdf:first sg:person.01152111734.09
112 rdf:rest N1e91a31c96434904ba3e2a592900ffe7
113 N9c041bf93d184dde99252cc9a53fb604 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
114 schema:name Biotransformation
115 rdf:type schema:DefinedTerm
116 Na150e925ed4c4f739dbd181d318fc973 rdf:first N48d8b92bb2f249b38349dce771c75fe7
117 rdf:rest Nb9227ca9a1474c2e991967715a1433f4
118 Na20e354d8c7a48bf869e1cce71997796 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
119 schema:name Healthy Volunteers
120 rdf:type schema:DefinedTerm
121 Nabb758d45c2b41ba9499004ecd086563 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
122 schema:name Male
123 rdf:type schema:DefinedTerm
124 Nb29bbaffb98f43f3b8e3bfaea885af1a schema:volumeNumber 74
125 rdf:type schema:PublicationVolume
126 Nb9227ca9a1474c2e991967715a1433f4 rdf:first sg:person.01254000765.20
127 rdf:rest Nd7147f82a070459ebaff76f865a00bfb
128 Nbb91ba206a174bf3b03b482b6a2d86d2 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
129 schema:name Adolescent
130 rdf:type schema:DefinedTerm
131 Nc0d28d1de42d46928e5e17f202f4933d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
132 schema:name Area Under Curve
133 rdf:type schema:DefinedTerm
134 Nc3e624b965254eceb8f9fa7155dc2c80 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
135 schema:name Benzyl Compounds
136 rdf:type schema:DefinedTerm
137 Nc66aa20676a9422a983d6447b0591a5d schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
138 schema:name Drug Interactions
139 rdf:type schema:DefinedTerm
140 Nce69c2a2fd4d4007bdf688d57a451356 schema:name dimensions_id
141 schema:value pub.1106131219
142 rdf:type schema:PropertyValue
143 Nd5f6ee49b950401bb851217f4f0a781a schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
144 schema:name Adult
145 rdf:type schema:DefinedTerm
146 Nd7147f82a070459ebaff76f865a00bfb rdf:first sg:person.0601142577.72
147 rdf:rest N642f9aaa74724d6c8f87980ab7cc87a4
148 Ndf0b16dba7754788b65e5292f3667631 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
149 schema:name Receptors, Lysosphingolipid
150 rdf:type schema:DefinedTerm
151 Ne10022fb8bff45d2b01b51189836726b schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
152 schema:name Enzyme Induction
153 rdf:type schema:DefinedTerm
154 Ne9aaf4f7b6694dd894b86d16e0ba3d48 schema:name doi
155 schema:value 10.1007/s00228-018-2533-2
156 rdf:type schema:PropertyValue
157 Neab00c28be5e4052904a5fb0fa1a9471 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
158 schema:name Lymphocyte Count
159 rdf:type schema:DefinedTerm
160 Neda1c6593546424788470e70d330c39f schema:name readcube_id
161 schema:value 407e2069a61a2f88a7fd2c7ae7441fb5601a5f500ea2bbbb43f66f98feb06e3b
162 rdf:type schema:PropertyValue
163 Nedffe90db8da4470871a81368d9e347e schema:name Springer Nature - SN SciGraph project
164 rdf:type schema:Organization
165 Nee9fe2109cf6424bb7dd7adc2b0bbfc8 schema:inDefinedTermSet https://www.nlm.nih.gov/mesh/
166 schema:name Rifampin
167 rdf:type schema:DefinedTerm
168 anzsrc-for:11 schema:inDefinedTermSet anzsrc-for:
169 schema:name Medical and Health Sciences
170 rdf:type schema:DefinedTerm
171 anzsrc-for:1103 schema:inDefinedTermSet anzsrc-for:
172 schema:name Clinical Sciences
173 rdf:type schema:DefinedTerm
174 sg:journal.1054337 schema:issn 0031-6970
175 1432-1041
176 schema:name European Journal of Clinical Pharmacology
177 rdf:type schema:Periodical
178 sg:person.01152111734.09 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
179 schema:familyName Legangneux
180 schema:givenName Eric
181 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01152111734.09
182 rdf:type schema:Person
183 sg:person.01254000765.20 schema:affiliation https://www.grid.ac/institutes/grid.464975.d
184 schema:familyName Neelakantham
185 schema:givenName Srikanth
186 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01254000765.20
187 rdf:type schema:Person
188 sg:person.01367544315.00 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
189 schema:familyName Shakeri-Nejad
190 schema:givenName Kasra
191 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.01367544315.00
192 rdf:type schema:Person
193 sg:person.0601142577.72 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
194 schema:familyName Huth
195 schema:givenName Felix
196 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0601142577.72
197 rdf:type schema:Person
198 sg:person.0716366542.41 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
199 schema:familyName Dumitras
200 schema:givenName Swati
201 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0716366542.41
202 rdf:type schema:Person
203 sg:person.0746041340.65 schema:affiliation https://www.grid.ac/institutes/grid.419481.1
204 schema:familyName Gardin
205 schema:givenName Anne
206 schema:sameAs https://app.dimensions.ai/discover/publication?and_facet_researcher=ur.0746041340.65
207 rdf:type schema:Person
208 sg:pub.10.1007/s00228-017-2404-2 schema:sameAs https://app.dimensions.ai/details/publication/pub.1099922651
209 https://doi.org/10.1007/s00228-017-2404-2
210 rdf:type schema:CreativeWork
211 sg:pub.10.1007/s40262-018-0700-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1106022094
212 https://doi.org/10.1007/s40262-018-0700-3
213 rdf:type schema:CreativeWork
214 sg:pub.10.1016/j.clpt.2004.08.009 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033907987
215 https://doi.org/10.1016/j.clpt.2004.08.009
216 rdf:type schema:CreativeWork
217 sg:pub.10.1016/j.clpt.2006.08.002 schema:sameAs https://app.dimensions.ai/details/publication/pub.1007524447
218 https://doi.org/10.1016/j.clpt.2006.08.002
219 rdf:type schema:CreativeWork
220 sg:pub.10.1186/s12974-016-0686-4 schema:sameAs https://app.dimensions.ai/details/publication/pub.1042047657
221 https://doi.org/10.1186/s12974-016-0686-4
222 rdf:type schema:CreativeWork
223 sg:pub.10.1208/s12248-012-9367-0 schema:sameAs https://app.dimensions.ai/details/publication/pub.1031115047
224 https://doi.org/10.1208/s12248-012-9367-0
225 rdf:type schema:CreativeWork
226 sg:pub.10.2165/00003088-200342090-00003 schema:sameAs https://app.dimensions.ai/details/publication/pub.1014227941
227 https://doi.org/10.2165/00003088-200342090-00003
228 rdf:type schema:CreativeWork
229 https://doi.org/10.1016/j.pharmthera.2007.04.006 schema:sameAs https://app.dimensions.ai/details/publication/pub.1050875697
230 rdf:type schema:CreativeWork
231 https://doi.org/10.1016/s0002-9440(10)64794-3 schema:sameAs https://app.dimensions.ai/details/publication/pub.1017653173
232 rdf:type schema:CreativeWork
233 https://doi.org/10.1016/s0140-6736(18)30475-6 schema:sameAs https://app.dimensions.ai/details/publication/pub.1101698897
234 rdf:type schema:CreativeWork
235 https://doi.org/10.1016/s1474-4422(13)70102-9 schema:sameAs https://app.dimensions.ai/details/publication/pub.1033439649
236 rdf:type schema:CreativeWork
237 https://doi.org/10.1073/pnas.1014154108 schema:sameAs https://app.dimensions.ai/details/publication/pub.1013336301
238 rdf:type schema:CreativeWork
239 https://doi.org/10.1093/brain/awq118 schema:sameAs https://app.dimensions.ai/details/publication/pub.1041480930
240 rdf:type schema:CreativeWork
241 https://doi.org/10.1093/rheumatology/ker018 schema:sameAs https://app.dimensions.ai/details/publication/pub.1022970028
242 rdf:type schema:CreativeWork
243 https://doi.org/10.1111/j.1365-2125.2012.04400.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1002553097
244 rdf:type schema:CreativeWork
245 https://doi.org/10.1111/j.1471-4159.2007.04629.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1045180467
246 rdf:type schema:CreativeWork
247 https://doi.org/10.1111/j.1471-4159.2007.4629.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1061939563
248 rdf:type schema:CreativeWork
249 https://doi.org/10.1111/j.1476-5381.2012.02061.x schema:sameAs https://app.dimensions.ai/details/publication/pub.1043127544
250 rdf:type schema:CreativeWork
251 https://doi.org/10.1124/dmd.106.010033 schema:sameAs https://app.dimensions.ai/details/publication/pub.1047422604
252 rdf:type schema:CreativeWork
253 https://doi.org/10.1124/dmd.109.027565 schema:sameAs https://app.dimensions.ai/details/publication/pub.1035576216
254 rdf:type schema:CreativeWork
255 https://doi.org/10.1124/dmd.117.079574 schema:sameAs https://app.dimensions.ai/details/publication/pub.1103850020
256 rdf:type schema:CreativeWork
257 https://doi.org/10.2174/157015910792246218 schema:sameAs https://app.dimensions.ai/details/publication/pub.1034815003
258 rdf:type schema:CreativeWork
259 https://doi.org/10.2217/pgs.10.49 schema:sameAs https://app.dimensions.ai/details/publication/pub.1020935714
260 rdf:type schema:CreativeWork
261 https://doi.org/10.5414/cp202369 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834516
262 rdf:type schema:CreativeWork
263 https://doi.org/10.5414/cp202588 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834626
264 rdf:type schema:CreativeWork
265 https://doi.org/10.5414/cp202608 schema:sameAs https://app.dimensions.ai/details/publication/pub.1072834636
266 rdf:type schema:CreativeWork
267 https://www.grid.ac/institutes/grid.418424.f schema:alternateName Novartis (United States)
268 schema:name Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
269 rdf:type schema:Organization
270 https://www.grid.ac/institutes/grid.419481.1 schema:alternateName Novartis (Switzerland)
271 schema:name Novartis Institutes for BioMedical Research, Basel, Switzerland
272 rdf:type schema:Organization
273 https://www.grid.ac/institutes/grid.423257.5 schema:alternateName Pharmaceutical Product Development (United States)
274 schema:name PPD, Austin, TX, USA
275 rdf:type schema:Organization
276 https://www.grid.ac/institutes/grid.464975.d schema:alternateName Novartis (India)
277 schema:name Novartis Healthcare Pvt. Ltd., Hyderabad, India
278 rdf:type schema:Organization
 




Preview window. Press ESC to close (or click here)


...